Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Ai |
RCV002223494 | SCV002501124 | uncertain significance | not provided | 2022-01-18 | criteria provided, single submitter | clinical testing | |
Fulgent Genetics, |
RCV002487024 | SCV002787043 | uncertain significance | Hypertrophic cardiomyopathy 4; Left ventricular noncompaction 10 | 2021-08-03 | criteria provided, single submitter | clinical testing | |
All of Us Research Program, |
RCV004808234 | SCV005430114 | uncertain significance | Hypertrophic cardiomyopathy | 2024-07-20 | criteria provided, single submitter | clinical testing | This missense variant replaces phenylalanine with serine at codon 12 of the MYBPC3 protein. Computational prediction suggests that this variant may have deleterious impact on protein structure and function (internally defined REVEL score threshold >= 0.7, PMID: 27666373). To our knowledge, functional studies have not been reported for this variant. This variant has not been reported in individuals affected with MYBPC3-related disorders in the literature. This variant has been identified in 1/231458 chromosomes in the general population by the Genome Aggregation Database (gnomAD). The available evidence is insufficient to determine the role of this variant in disease conclusively. Therefore, this variant is classified as a Variant of Uncertain Significance. |